PITTSBURGH, Sept. 21 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today obtained a temporary restraining order from the U.S. District Court for the District of New Jersey that prohibits Apotex from "using, offering to sell, selling or shipping or otherwise launching or importing" all three strengths of a generic version of GlaxoSmithKline's Paxil CR, Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, 12.5 mg, 25 mg and 37.5 mg. The order also prohibits GlaxoSmithKline from supplying Apotex with a generic version of the product. The order was entered today, and the court has scheduled further hearings on the matter for Oct. 18.
Mylan is currently selling all three strengths of Paroxetine HCl ER.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.
SOURCE Mylan Inc.